Outbreaks and sporadic cases of meningococcal disease among college students have prompted consideration of a policy of routine vaccination for this group.
Purchase and administration of the vaccine for routine vaccination would cost $56 million per year.
Savings in medical care and indirect costs would not equal this amount unless the annual rate of disease among students is at least 6.5/100 000.
The actual rate among students is unknown ; however, surveillance data suggest it could not be more than 1.3/100 000.
At rates near this estimate, the net cost of the program would be approximately $45 million annually.
More cost-effective prevention strategies might be yielded by further studies to identify students at substantial risk of meningoccocal disease, or by the development for a conjugate serogroup C vaccine that could be administered during infancy.
Mots-clés Pascal : Méningococcie, Bactériose, Infection, Vaccination, Prévention, Etudiant, Université, Adulte jeune, Homme, Evaluation, Analyse avantage coût, Economie santé, Etats Unis, Amérique du Nord, Amérique
Mots-clés Pascal anglais : Meningococcal disease, Bacteriosis, Infection, Vaccination, Prevention, Student, University, Young adult, Human, Evaluation, Cost benefit analysis, Health economy, United States, North America, America
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 95-0350850
Code Inist : 002B05B02I. Création : 01/03/1996.